Prevent tremor relapse after thalamotomy
- Trial ID
- NCT07284719
- Official Title
- Predictors and Mechanisms of Tremor Relapse After MR-Guided Focused Ultrasound Thalamotomy in Parkinson's Disease
- Goal
- Prevent tremor relapse after thalamotomy
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Aarhus University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson s Disease, Tremor
- Interventions
- MR-guided focused ultrasound thalamotomy
Plain-Language Summary
The goal is to find why tremor sometimes comes back after MR-guided focused ultrasound thalamotomy, by identifying clinical and brain-imaging predictors and underlying mechanisms of relapse. The approach uses MRI to aim focused ultrasound beams through the skull to heat and ablate a very small spot in the thalamus that drives tremor, interrupting the tremor circuit without open brain surgery, and then follows patients over time to see what changes predict return of tremor. This procedure does not change how levodopa replaces dopamine for other Parkinson symptoms, though it may reduce tremor and the need for tremor-specific medications in some people. The trial is enrolling people aged 50 to 80 with idiopathic Parkinsons whose tremor is not manageable with optimal medication, with Hoehn and Yahr stage under 3, adequate skull density for ultrasound, ability to have MRI and lie flat for a few hours, and without dementia, major psychiatric or other MRI contraindications.
Locations
- Aarhus University Hospital, Aarhus, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying MR-guided focused ultrasound thalamotomy. The goal is to find why tremor sometimes comes back after MR-guided focused ultrasound thalamotomy, by identifying clinical and brain-imaging predictors and underlying mechanisms of relapse. The approach uses MRI to aim focused ultrasound beams through the skull to heat and ablate a very small spot in the thalamus that drives tremor, interrupting the tremor circuit without open brain surgery, and then follows patients over time to see what changes predict return of tremor. This procedure does not change how levodopa replaces dopamine for other Parkinson symptoms, though it may reduce tremor and the need for tremor-specific medications in some people. The trial is enrolling people aged 50 to 80 with idiopathic Parkinsons whose tremor is not manageable with optimal medication, with Hoehn and Yahr stage under 3, adequate skull density for ultrasound, ability to have MRI and lie flat for a few hours, and without dementia, major psychiatric or other MRI contraindications.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.